Pixelgen Technologies Releases MPX v2 for Enhanced Cell Surface Protein Phenotyping and Colocalization Analysis

Stockholm, July 15, 2024Pixelgen Technologies, a leader in spatial proteomics for single cells, announced today the release of the Pixelgen Single Cell Spatial Proteomics Kit, Immunology Panel 2, Human v2 (MPX v2) for enhanced cell surface protein phenotyping and colocalization analysis. The upgraded kit offers a 3.7-fold increase in signal-to-noise ratio, 2.2 times more data per cell, and stronger antibody performance compared with the company’s first commercial product.

“Since the launch of our first commercial product last year, we’ve been honored to work with prominent researchers and industry leaders who’ve adopted our Molecular Pixelation kit to add a new dimension to their cell activity studies,” said Simon Fredriksson, CEO & Co-founder of Pixelgen Technologies. “Today, we’re extremely pleased to offer our customers and the life sciences research community an even more powerful version of MPX, ideally suited to advance research in immuno-oncology, immunotherapy, CAR-T, and hematology.”

MPX v2 offers an 84-target panel and detects known protein interaction complexes, such as CD11a – CD18 (LFA-1), CD29-CD49D (VLA-4) and HLA-ABC – B2M and detects novel ones. The enhancements in MPX v2 come from Pixelgen’s continual efforts to innovate to better serve its customers, and more specifically are a result of optimization to the MPX chemistry, updates to the “Immunology Panel 2, Human” and optimized algorithms for the spatial metrics found in the Pixelator software. More information may be found in this Technology Note (link to tech note).

About Pixelgen Technologies
Pixelgen Technologies AB was founded in 2020 by a team of passionate, experienced innovators and entrepreneurs with a vision to bring a new spatial understanding to biology by mapping cell surface proteins and their spatial inter-relationships. The company has developed Molecular Pixelation, a DNA-based visualization technology for analyzing cell surface proteins, to gain novel insights into cellular activity that will advance better medicines and diagnostics. Pixelgen is headquartered in Stockholm, Sweden.

Contacts

Corporate:
Annika Branting
annika.branting@pixelgen.com
+46 762-69 68 46

Media:
Susan Thomas
susan@endpointcommunications.net
+1 (619) 540-9195

Pixelgen Technologies

Contact us

Send a message

Contact